OrthoPediatrics Corp. filings document the regulatory record of a Nasdaq-listed medical device company focused on pediatric orthopedics. Its Form 8-K reports include quarterly and annual results, unaudited financial statements, revenue trends across Trauma and Deformity, Scoliosis, Sports Medicine/Other and OrthoPediatrics Specialty Bracing, as well as management guidance and investor presentation materials furnished under Regulation FD.
The company’s filings also cover governance and ownership matters through proxy statements, including board elections, executive compensation and equity awards. Material-event filings describe financing arrangements such as amendments to credit agreements and delayed draw term loan capacity, tying capital structure disclosures to the company’s operating and liquidity needs.
ORTHOPEDIATRICS CORP (KIDS) reported that Squadron Capital LLC, a ten percent owner, sold a total of 336,831 shares of common stock in two open-market transactions. On August 28, 2026 it sold 326,700 shares at a weighted average price of $23.04 per share, with individual prices ranging from $23.00 to $23.82. On September 1, 2026 it sold 10,131 shares at a weighted average price of $23.10, with individual prices ranging from $23.00 to $23.58. The footnotes state the sale by Squadron Capital LLC was undertaken to provide additional capital for its other portfolio businesses, and that Squadron Capital Holdings LLC is the controlling member of Squadron Capital LLC.
OrthoPediatrics Corp. (KIDS) has an amended Schedule 13D (Amendment No. 3) reporting updated ownership and recent share sales by Squadron Capital LLC and related parties. Squadron Capital LLC directly holds 6,526,633 shares of common stock, representing 25.0% of the outstanding shares, based on 26,109,788 shares outstanding as of August 4, 2026.
Through direct and indirect holdings, Jennifer N. Pritzker is deemed to beneficially own 6,541,340 shares (about 25.1%), and David R. Pelizzon is deemed to beneficially own 6,571,017 shares (about 25.2%). Squadron Capital LLC executed several open-market sales between August 24 and September 1, 2026 at weighted average prices between $23.04 and $25.75, stated as undertaken to provide additional capital for its other portfolio businesses.
ORTHOPEDIATRICS CORP (KIDS) reported insider activity by ten percent owner Jennifer N. Pritzker, relating primarily to sales by Squadron Capital LLC, an entity with which she is associated. Squadron sold 326,700 shares of common stock on August 28, 2026 at a weighted average price of $23.04 per share (individual trades ranged from $23.00–$23.82), and later sold 10,131 shares on September 1, 2026 at a weighted average price of $23.10 (trades from $23.00–$23.58). The filing shows a separate direct holding of 10,900 shares of common stock for the reporting person as of August 28, 2026. For the indirect holdings, the reporting person may be deemed a beneficial owner through Squadron and several related foundations and entities but expressly disclaims beneficial ownership except to the extent of her pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) insider reporting person David R. Pelizzon, a director and ten percent owner, reported indirect sales of Orthopediatrics common stock carried out by Squadron Capital LLC. Squadron sold a total of 336,831 shares on August 28 and September 1, 2026 at weighted average prices in the low‑$23 range, with prices ranging from $23.00 to about $23.82. Pelizzon is President and a member of Squadron’s Managing Committee and may be deemed a beneficial owner of these indirectly held shares, but he expressly disclaims beneficial ownership except to the extent of his pecuniary interest. He also reports 44,384 shares of common stock held directly, including 17,959 restricted stock awards.
ORTHOPEDIATRICS CORP (KIDS) reported that Jennifer N. Pritzker, a ten percent owner, filed a Form 4 showing indirect sales of an aggregate 38,300 shares of common stock on August 24–26, 2026. The sales were executed by Squadron Capital LLC, a manager-managed LLC, at weighted average prices around the mid-$20s per share, with detailed price ranges disclosed in footnotes. Pritzker reports 10,900 shares held directly and disclaims beneficial ownership of the indirectly held shares except to the extent of her pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) reported insider activity by large shareholder entities Squadron Capital LLC and Squadron Capital Holdings LLC. Squadron Capital LLC sold a total of 38,300 shares of Common Stock over August 24–26, 2026 in open-market transactions at weighted-average prices between about $24.13 and $25.82 per share. The filing states the sales were undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses. The shares are held directly by Squadron Capital LLC, and Squadron Capital Holdings LLC is its controlling member.
ORTHOPEDIATRICS CORP (KIDS) received a Form 4 from director and ten percent owner David R. Pelizzon reporting sales of common stock held indirectly through Squadron Capital LLC. On 2026-08-24, 2026-08-25, and 2026-08-26, Squadron sold a total of 38,300 shares of Orthopediatrics common stock in open-market or private transactions at weighted average prices reported as $25.75, $24.74, and $24.28 per share, each with detailed price ranges provided in footnotes. A separate entry shows Pelizzon holding 44,384 shares directly as of 2026-08-24, including 17,959 restricted stock shares. Footnotes state the sales were undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses and that Pelizzon may be deemed a beneficial owner through his role at Squadron but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.
ORTHOPEDIATRICS CORP (KIDS) had a large shareholder, Squadron Capital, LLC, file a notice of proposed sale of common stock under Rule 144. Squadron, identified as a 10% stockholder, plans to sell up to 700,000 shares of KIDS common stock through broker Stifel Nicolaus & Company Inc.
The filing lists an aggregate market value of approximately $18,361,000 for these shares and states there are 26,109,788 shares of common stock outstanding. Squadron notes that the shares to be sold represent about 10% of its holdings and that the sale is intended to provide additional capital for its other portfolio businesses.
The shares being sold were originally acquired from the issuer on 09/20/2022 through a purchase of 1,525,000 common shares, with consideration described as cash plus forgiveness of debt, with payment dated 08/15/2022. The notice is dated 08/24/2026.
OrthoPediatrics Corp. reported Q2 2026 net revenue of $70.5 million, up 15% from $61.1 million, with first‑half revenue rising 14% to $129.9 million. Growth was led by trauma and deformity products, where Q2 sales increased 26% to $52.6 million, while scoliosis Q2 revenue declined 9% to $16.9 million. Gross margin improved to 74% from 72% for both the quarter and year‑to‑date.
Q2 operating loss narrowed to $4.1 million from $10.7 million, but higher interest expense turned prior‑year other income into expense, leaving Q2 net loss essentially flat at $7.2 million (EPS $(0.30)). First‑half net loss was $17.9 million, or $(0.75) per share. At June 30, 2026, cash, restricted cash and short‑term investments totaled $47.9 million against total debt of $105.8 million, including a $51.0 million term loan and $50.0 million of 4.75% convertible notes due 2030. Net cash used in operating activities improved to $2.4 million from $14.6 million a year earlier. Management states that existing cash, expected cash flows and an undrawn $20.0 million delayed draw term loan under the Braidwell amendment are expected to support operations for more than 12 months.
OrthoPediatrics Corp., a company focused exclusively on pediatric orthopedics, presents an investor update highlighting a $6.2B global addressable market and a strategy centered on child-specific implants, a broad product portfolio, global sales coverage and extensive clinical education for pediatric orthopedic surgeons.
The company reports steady revenue expansion, with 2025 revenue of $236.3 million versus $204.7 million in 2024, and 2Q 2026 revenue of $70.5 million compared with $61.1 million in 2Q 2025. Despite growth, OrthoPediatrics continues to post net losses, including a 2025 diluted EPS of $(1.69).
Management provides 2026 guidance for revenue of $265.0–$269.0 million, Adjusted EBITDA of approximately $25.0 million and roughly breakeven free cash flow. As of June 30, 2026, the balance sheet shows $47.9 million in cash and short-term investments and $99.6 million of debt. The presentation also outlines a multi-year “super-cycle” of differentiated pediatric product launches and explains non-GAAP measures such as Adjusted EBITDA, adjusted diluted loss per share and free cash flow used in assessing operating performance.